^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Whole exome and transcriptome sequencing of colorectal and pancreatic cancer.
Published date:
05/28/2020
Excerpt:
A 66 yr old pt with neoplasm of rectosigmoid junction tumor was found to be KRAS wildtype and was treated with cetuximab plus FOLFIRI. Patient failed therapy after 2 yrs and sequencing revealed MET amplification which is a known mechanism of resistance to cetuximab treatment. Further, RNA expression analysis showed 44-fold increase in MET expression along with overexpression of AREG and EREG.
Secondary therapy:
FOLFIRI
DOI:
10.1200/JCO.2020.38.15_suppl.e15666
